Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Greenwich LifeSciences ( (GLSI) ) has provided an announcement.
On December 18, 2025, Greenwich LifeSciences, Inc. held its Annual Meeting of Stockholders, at which 8,944,615 shares of common stock were represented in person or by proxy, constituting a quorum. Stockholders elected all five director nominees—David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock—to serve until the 2025 Annual Meeting or until their successors are duly elected and qualified, and ratified the appointment of MaloneBailey LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, reinforcing continuity in both the board’s composition and the company’s audit oversight.
The most recent analyst rating on (GLSI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Greenwich LifeSciences stock, see the GLSI Stock Forecast page.
More about Greenwich LifeSciences
Greenwich LifeSciences, Inc. is a biopharmaceutical company focused on developing immunotherapies for the treatment of breast cancer and potentially other solid tumors, targeting the oncology market with clinical-stage therapeutic candidates.
Average Trading Volume: 148,843
Technical Sentiment Signal: Hold
Current Market Cap: $144.1M
See more insights into GLSI stock on TipRanks’ Stock Analysis page.